SWITZERLAND – Roche has elected Teresa Graham as its new Chief Executive Officer (CEO) of Roche Pharmaceuticals and a member of the Corporate Executive Committee, effective March 2023. Teresa Graham will report to Thomas Schinecker, the Roche Group CEO, the pharmaceutical company announced in a statement. The recently appointed CEO of Roche Pharma will focus on its commitment to science and innovation, which are the core tenets for ensuring a strong pipeline of medicines and the company’s future success. Graham brings a deep understanding of Roche’s operations and is well-positioned to continue steering the company’s business in Switzerland. In addition, the strategic leader currently serves as the Head of Global Product Strategy for Roche Pharmaceuticals and she has progressed through multiple positions at the global company. Prior to her current role, Teresa Graham was in charge of product management at Genentech in 2005. In the United States, Genentech is a wholly owned member of the Roche Group. She served as a sales manager at the independent center within Roche in 2010 before taking over the Marketing Director role for Rituxan Immunology and subsequently for Actemra. Moreover, Graham was instrumental in the growth and development of the product portfolio for Genentech until she was appointed to her current role in 2019. Besides being a George Washington University alumnus, she is a Global Board Member for the Healthcare Businesswomen’s Association, where she has served in multiple capacities spanning over 10 years. Commenting on her appointment, Thomas Schinecker said: “Teresa Graham is a great leader with strong followership. She brings strategic and scientific acumen with an excellent track record of performance. I am pleased that a person of her caliber will be our new Pharma CEO.” At the same time, Roche has elected Levi Garraway, Executive Vice President, Head of Global Product Development and Chief Medical Officer at Genentech, to join its enlarged Corporate Executive Committee. Scientist Levi Garraway will report to the Roche Group CEO, Thomas Schinecker, when he takes over the role in March 2023. “Levi Garraway is an excellent addition to the executive committee. I highly regard his thoughtful, scientific, and data-driven approach to our late-stage portfolio and his dedication to bringing innovative medicines to patients,” Severin Schwan, former Roche Group CEO, said. In addition to serving on the advisory boards of major cancer centers, the renowned clinician has led research teams that made multiple breakthrough discoveries in cancer genomics, drug resistance, and precision medicine. For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.